| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fedfec6fcbe928c5bd56e3c5530f456
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49f673efd2b8f2ce37c4de74543a33a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_100b8bc388439e9380ec13661a652ca6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f70c1c4ba071d62460b17f9f396a1aa8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bc00224f3e7a9e439147b607a5067a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ae28382d84e17eab99d23d05f88c7c5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43522 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 |
| filingDate |
2001-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1309656775312b6214548a68f92dcb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7a40029c176b85002cc06917516286d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60d7f30a3419b2724fb8c99b1fa62d62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5dad575ceb8046dabbd6d9a097037e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b4e841b31d1ca999277128677084475 |
| publicationDate |
2001-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0164724-A2 |
| titleOfInvention |
Maurocalcine, analogues thereof and their therapeutical uses |
| abstract |
Maurocalcine, a novel toxin isolated from the venom of the Tunisian chactidae scorpion Scorpio maurus palmatus, has the amino acid sequence GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR (SEQ. ID. No. 1). It potently and reversibly modifies channel gating behaviour of type 1 ryanodine receptor (RyR1) by inducing prominent subconductance behavior. Maurocalcine and its bioactive structural analogues - preferably those containing the KKCKRR motif corresponding to part of the II-III loop of the alpha1S subunit of the voltage-dependent skeletal muscle calcium channel dihydropyridine receptor - appear to possess a therapeutic potential, notably as candidate immuno-suppressive drugs, and for the treatment of pathologies in humans that may involve a dysfunction of calcium channels. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1392344-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2877946-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8207293-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008519592-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006051224-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1392344-A4 |
| priorityDate |
2000-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |